A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)

Protocol No
GSK-207495-DREAMM-03
Principal Investigator
Binod Dhakal
Phase
III
Summary
The study will test if the investigational study treatment, called belantamab mafodotin (also referred to as GSK2857916), can help patients with worsening MM who have already failed at least two other treatments (called relapsed/refractory MM).
Description
Belantamab mafodotin vs pom/dex in RRMM
Participating Institutions
Froedtert Hospital
Status
IRB INITIAL APPROVAL
Share This: